LENZ Therapeutics, Inc. Common Stock (LENZ) Stock Price
LENZStock
$4.67−88.53%52W
Market Cap$146.73M
P/E—
PEG Ratio—
Div yield—
Beta1.97
LENZ Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-75.30%
Price vs S&P 500 (4W)-24.99%
VGM Score13.63
LENZ Earnings Surprise History
Q2 25-0.53est. -0.54
Q3 25-0.59est. -0.67
Q4 25-1.16est. -0.92
Q1 26-1.32est. -1.07
Q2 26-1.02est. -1.07
LENZ Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.38
4.31
4.31
4.31
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LENZLENZ Therapeutics, Inc. Common Stock | — | — | F | $4.67 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About LENZ Therapeutics, Inc. Common Stock
LENZ Therapeutics is a late-stage biopharmaceutical company developing ophthalmic treatments for presbyopia, the age-related loss of near vision affecting the majority of people over 45. The company is advancing therapies to address this widespread condition in a large and growing market.